ABO-incompatible cardiac transplantation in pediatric patients with high isohemagglutinin titers

J Heart Lung Transplant. 2015 Aug;34(8):1095-102. doi: 10.1016/j.healun.2015.03.013. Epub 2015 Mar 26.

Abstract

Background: ABO-incompatible (ABOi) cardiac transplantation is now used widely in infants with isohemagglutinin titers <1:4, but there is increasing evidence that ABOi transplantation can also be used in children with significantly higher titers. We reviewed our high-titer ABOi transplants and report our results here.

Methods: Patients who underwent ABOi cardiac transplantation from 2000 to 2013 with pre-existing isohemagglutinin titers of ≥1:16 were identified from departmental databases. Outcomes were reviewed using medical and laboratory records.

Results: Thirty patients underwent ABOi cardiac transplantation between 2000 and 2013. Twelve (40%) had pre-transplant isohemagglutinin titers of ≥1:16 and were included for further study. Median age was 14.9 (range 9.8 to 107.3) months and median weight was 9.6 (range 7.6 to 25) kg. Five (42%) were male. Pre-transplant diagnosis was cardiomyopathy in 8 of 12 (67%) and congenital heart disease in 4 of 12 (33%). Highest pre-transplant isohemagglutinin titer was 1:256 in 2 patients. Four patients (33%) had early antibody-mediated rejection (AMR), all within 15 days post-transplant. Management included use of rituximab, bortezomib, immunoadsorption and eculizumab. Three patients died but no deaths were associated with high isohemagglutinin titers.

Conclusions: ABOi cardiac transplantation in patients with isohemagglutinin titers ≥1:16 is possible. AMR may occur early and immunoadsorption has proven effective at decreasing antibody titers.

Keywords: ABO-incompatible; cardiac transplantation; high isohemagglutinin titers; pediatric.

MeSH terms

  • ABO Blood-Group System*
  • Blood Group Incompatibility*
  • Child
  • Child, Preschool
  • Female
  • Heart Failure / blood*
  • Heart Failure / etiology
  • Heart Failure / surgery*
  • Heart Transplantation*
  • Hemagglutinins / blood*
  • Humans
  • Infant
  • Male
  • Retrospective Studies
  • Treatment Outcome
  • United Kingdom

Substances

  • ABO Blood-Group System
  • Hemagglutinins